pocketful logo light
pocketful logo light
Glenmark Pharmaceuticals Ltd logo

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK BSE: 532296

2419.20

(0.17%)

Sun, 20 Sept 2026, 08:48 pm

Glenmark Pharmaceuticals Share Price Live Chart

1 Day

(0.17%)

No Result Found

Summary

  • Market Cap (in Cr)

    64179.52

  • Net Profit (in Cr)

    1047.14

  • P/B

    4.91

  • Sector P/E

    33.76

  • P/E

    41.50

  • EV/EBITDA

    21.14

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    15.79

  • ROCE

    18.48

  • Debt/Equity

    0.22

  • EPS (TTM)

    95.92

  • Dividend Yield

    0.11

  • Book Value

    339.54

  • Interest Cover

    9.56

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters46.6546.6546.6546.6546.65
FII20.3419.2020.7320.6223.16
DII19.2920.0918.6117.6414.60
Public13.6814.0213.9715.0615.56
Government0.040.040.040.040.04

Read More

Technical Analysis

RSI

57.87

MACD

26.68

50 DMA

2329.11

200 DMA

2180.22

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic3144.402768.802624.402393.202248.802017.601642.00
Fibonacci2768.802625.322536.682393.202249.722161.082017.60
Camarilla2583.292548.862514.432393.202445.572411.142376.71

Pivots Level: Classic

R3

+751.20

3144.40

R2

+375.60

2768.80

R1

+231.20

2624.40

2393.20
2393.20
Pivot Point
LTP: 2447.40

S1

-144.40

2248.80

S2

-375.60

2017.60

S3

-751.20

1642.00

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2424.82

  • 20-EMA

    2410.22

  • 30-EMA

    2388.13

  • 50-EMA

    2351.68

  • 100-EMA

    2290.06

  • 200-EMA

    2185.06

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 May 2026board-meetingsAccounts, Final Dividend
30 Jan 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
26 Sept 2025dividend₹2.50 Dividend /Share03 Oct 2025
03 Sept 2025dividendInterim Dividend - Rs. - 2.503 Oct 2025
22 Aug 2025agm
15 Aug 2025dividendFinal Dividend - Rs. - 2.515 Sept 2025
23 May 2025dividend₹2.50 Dividend /Share15 Sept 2025
30 Aug 2024agm
13 Aug 2024dividendDividend - Rs 2.50 Per Share17 Sept 2024

Read More

Peer Comparison

Glenmark Pharmaceuticals Ltd logo

Glenmark Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Glenmark Pharmaceuticals Ltd About

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1977

Headquarters

CEO

Glenn Saldanha

Employees

Contact

Website icon

Website

http://www.glenmarkpharma.com

Email icon

Email

complianceofficer@glenmarkpharma.com

Phone icon

Phone

91-22-40189999

Location icon

Location

B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026

Read More

Glenmark Pharmaceuticals Ltd Company History

YearHistory
2020
  • First to launch Remogliflozin + Vildagliptin FDC for Type 2 Diabetes in India.
  • Introduced NINDANIB (Nintedanib) for Pulmonary Fibrosis in India.
  • Introduced 400 mg strength FabiFlu for COVID-19 treatment.
  • Received USFDA approval for Deferasirox tablets for oral suspension.
  • Pledged 50 lakh meals amid COVID-19 pandemic.
  • Entered exclusive licensing agreement with Hikma for Ryaltris in US.
2021
  • Awarded International Safety Award.
  • Awarded Environmental, Social and Governance Summit & Awards.
  • Launched Rufinamide Tablets USP 200 mg and 400 mg.
  • Launched Ryaltris nasal spray in India.
2022
  • Received USFDA approval for Nicardipine Hydrochloride capsules.
  • Received ANDA approval for generic birth control drug.
  • Received India Pharma Innovation of the Year Award from Government of India.
  • First to launch Triple FDC Teneligliptin + Pioglitazone + Metformin for Type 2 Diabetes in India.
  • Launched Fingolimod Capsules 0.5 mg in US.
2023
  • Launched Bumetanide Injection USP 1 mg/4 mL and 2.5 mg/10 mL in US.
2024
  • Received US health regulator approval for generic stomach acid medication.
  • Launched Lacosamide Oral Solution 10 mg/mL in US.
  • Launched Travoprost Ophthalmic Solution USP 0.004% in US.
  • Received ANDA approval for Topiramate Capsules USP 15 mg and 25 mg.
  • Entered agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkSell15105912173.3111 Jul 2025
GRAVITON RESEARCH CAPITAL LLPbulkBuy15105912171.6711 Jul 2025
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.blockBuy2644651492.6525 Mar 2025
UBS AGblockSell2644651492.6525 Mar 2025
UBS PRINCIPAL CAPITAL ASIA LIMITEDblockSell671394151023 Jan 2025
UBS AGblockBuy671394151023 Jan 2025
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy39265397.925 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy302621397.925 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell302621397.925 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell39265397.925 Oct 2022

Read More

Glenmark Pharmaceuticals Ltd News

Glenmark AGM: Dividend, Financials Approved

Glenmark Pharmaceuticals shareholders approved FY26 financials and a ₹2.50 dividend at the 48th AGM. Mrs. Blanche Saldanha was reappointed as a Non-Executive Director.

11 Sept 2026

companies

Glenmark launches RYALTRIS Nasal Spray in Brazil

Glenmark Pharmaceuticals expands its global respiratory innovation footprint with the launch of RYALTRIS Nasal Spray in Brazil. The dual-action therapy treats allergic rhinitis symptoms in adults and adolescents, following ANVISA approval.

11 Sept 2026

companies

Glenmark Pharma Q1 Results: Net Profit Surges to ₹4.83B

Glenmark Pharmaceuticals reports Q1 consolidated net profit of ₹4.83B rupees vs ₹469M YoY, with revenue rising to ₹40.2B and EBITDA margin expanding to 19.51%.

31 Jul 2026

companies

Glenmark launches Sugammadex in US

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, targeting a $1.6 billion market. The generic is bioequivalent to Merck's BRIDION.

28 Jul 2026

companies

Glenmark Pharma Eyes 70% Revenue From Innovative Drugs

Glenmark Pharma expects 70% of its revenue to come from innovative drugs within 5-6 years, signalling a strategic shift toward an innovation-based business model.

22 Jul 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Glenmark Pharmaceuticals Ltd?

    As of 21/09/2026 at 2:18 AM, Glenmark Pharmaceuticals Ltd shares are trading at 2419.20.

  • 2.What is the market cap. of Glenmark Pharmaceuticals Ltd?

    As of 21/09/2026, the market capitalization of Glenmark Pharmaceuticals Ltd is 68,213.71 crore.

  • 3.When was Glenmark Pharmaceuticals Ltd founded?

    Glenmark Pharmaceuticals Ltd was founded in 1977.

  • 4.What are the P/E and P/B ratios of Glenmark Pharmaceuticals Ltd?

    As of 21/09/2026, Glenmark Pharmaceuticals Ltd has a P/E ratio of 37.98 and a P/B ratio of 4.91.

  • 5.How can I buy shares of Glenmark Pharmaceuticals Ltd?

    You can buy shares of Glenmark Pharmaceuticals Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?

    As of March,2026, promoters hold 46.65% in Glenmark Pharmaceuticals Ltd, while FIIs, DIIs and public shareholders hold 20.34%, 19.29% and 13.68%, respectively. The government holds 0.04%.

  • 7.Does Glenmark Pharmaceuticals Ltd pay dividends?

    Yes, Glenmark Pharmaceuticals Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹2.50 Dividend /Share per share.

  • 8.What is the dividend yield of Glenmark Pharmaceuticals Ltd?

    As of 21 September, 2026, the dividend yield of Glenmark Pharmaceuticals Ltd stands at 0.21%.

  • 9.What are the latest financial results of Glenmark Pharmaceuticals Ltd?

    For January,2024, Glenmark Pharmaceuticals Ltd reported revenue of 13,322.00 crore and a net profit of 1,047.00 crore.

  • 10.What is the Stock symbol of Glenmark Pharmaceuticals Ltd?

    GLENMARK is the stock symbol of Glenmark Pharmaceuticals Ltd.

  • 11.Who is the CEO of Glenmark Pharmaceuticals Ltd?

    The CEO of Glenmark Pharmaceuticals Ltd is Glenn Saldanha.

Open Your Free Demat Account

Enter your phone number